Ryan Haumschild, PharmD, MS, MBA, CPEL

Lorlatinib’s Unique Adverse Event Profile Key Themes: Cognitive effects, hypercholesterolemia, and peripheral neuropathy with lorlatinib Impact of adverse events on treatment selection Monitoring and management of cholesterol levels Notable Insights: Dr Dietrich discussed lorlatinib’s unique adverse event profile and its […]

PBM-Driven Biosimilar Adoption: Lessons for Physicians Strategic Formulary Changes and Market Impact Recent decisions by major PBMs to designate biosimilars as preferred agents over reference biologics provide the following valuable insights into effective adoption strategies: Formulary design is a powerful

Preparing for Interchangeable Biosimilars: Guidance for Physicians Stakeholder Preparation for Interchangeability Designations With more biosimilars expected to receive interchangeability designations later this year, health care stakeholders should prepare by the following: Developing clear policies and protocols for automatic substitution Establishing

ALK Inhibitor Comparison and CNS Penetration Key Themes: Overview of currently available ALK inhibitors in the metastatic setting Comparative analysis of efficacy and durability of response Differences in CNS penetration among ALK inhibitors Notable Insights: Dr Lovly provided a comprehensive

ALK Inhibitor Tolerability and Toxicity Management Key Themes: Tolerability comparison among available ALK inhibitors Best practices for managing treatment-associated toxicities Patient management strategies Notable Insights: Castronovo compared the tolerability profiles of various ALK inhibitors Grizzard shared best practices for toxicity

Biosimilars in Health Care: Market Dynamics and Implementation Strategies Rising Biologics Costs and Market Opportunity Reference biologics have experienced significant price increases over the past decade, creating market demand for more affordable biosimilar alternatives. This price inflation has important implications

Biosimilars Pricing Strategies and Private Label Agreements: A Summary for Physicians Dual Pricing Strategies for Biosimilars Manufacturers of biosimilars often offer both high-WAC and low-WAC versions of their products for several strategic reasons, including the following: To navigate the complex

Comparative Data Analysis and Ensartinib Approval Key Themes: Matching-adjusted indirect comparisons (MAIC) of lorlatinib versus alectinib or brigatinib Overview of the eXalt3 study for ensartinib Implications of ensartinib’s December 2024 FDA approval Notable Insights: Dr Dietrich analyzed insights from the

Real-World Settings and Evolution of Frontline Therapy Key Themes: Comparison of clinical trial outcomes to real-world patient experiences Impact of clinical data (ALINA, CROWN, eXalt3) on frontline therapy choices Evolving perspective on frontline therapies for ALK+ NSCLC Notable Insights: Grizzard

Opinion Video March 14, 2025 Panelists discuss challenges oncologists face in managing treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including balancing efficacy with adverse effect profiles, and highlight strategies such as multidisciplinary collaboration and access